|
KMID : 0032220220340030173
|
|
Annals of Dermatology
2022 Volume.34 No. 3 p.173 ~ p.181
|
|
|
Association Between Short-Term PASI90 Achievement and Drug Survival of Biologics in Patients with Psoriasis
|
|
Choi Sung-Jun
Oh So-Hee
Yoon Hyun-Sun
|
|
|
Abstract
|
|
|
Background: With accumulating evidence that achieving a 90% improvement in the Psoriasis Area and Severity Index score (PASI90) has better correlation with improved health-related quality of life as compared to PASI75 achievement, there has been demand for establishing new treatment goals for psoriasis. We investigated whether the short-term PASI90 achievement would predict longer drug survival as compared to PASI75 achievement.
Objective: We investigated whether the short-term PASI90 achievement would predict longer drug survival as compared to PASI75 achievement.
Methods: This single-center retrospective cohort study reviewed 180 treatment series in 128 patients with plaque psoriasis, who were treated with tumor necrosis factor-alpha inhibitors (n=12), ustekinumab (n=88), secukinumab (n=23), guselkumab (n=45), and ixekizumab (n=12). The first effectiveness assessment, usually performed within 12 to 20 weeks, was considered a short-term treatment response to biologics.
Results: After adjustment for covariates, time-dependent Cox proportional hazards regression analysis showed that moderate responders (short-term achievement of ≥PASI75 but
Conclusion: The short-term PASI90 achievement is a better predictor of longer drug survival as compared to PASI75 achievement.
|
|
|
KEYWORD
|
|
|
Biological products, Prognostic factor, Psoriasis, Survival analysis, Treatment outcome
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|
|